Profound Medical SG&A Expenses 2020-2024 | PROF

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Profound Medical sg&a expenses from 2020 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Profound Medical sg&a expenses from 2020 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$79.8B
Takeda Pharmaceutical (TAK)	$43.8B
Merck (MKKGY)	$21B
Astellas Pharma (ALPMY)	$20.2B
Sandoz Group AG (SDZNY)	$19.8B
United Therapeutics (UTHR)	$18.3B
Summit Therapeutics (SMMT)	$15.8B
Neurocrine Biosciences (NBIX)	$12.7B
Shionogi (SGIOY)	$12.5B
Catalent (CTLT)	$10.8B
Madrigal Pharmaceuticals (MDGL)	$7.6B
Jazz Pharmaceuticals (JAZZ)	$7.6B
Orion OYJ (ORINY)	$6.8B
Corcept Therapeutics (CORT)	$6.2B
Ionis Pharmaceuticals (IONS)	$6.2B
Crinetics Pharmaceuticals (CRNX)	$4.9B
PTC Therapeutics (PTCT)	$3.4B
Dyne Therapeutics (DYN)	$2.9B
Catalyst Pharmaceuticals (CPRX)	$2.9B
Arrowhead Pharmaceuticals (ARWR)	$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.7B
Soleno Therapeutics (SLNO)	$2.5B
NewAmsterdam Pharma (NAMS)	$2.2B
Recursion Pharmaceuticals (RXRX)	$2B
Centessa Pharmaceuticals (CNTA)	$1.9B
Harrow (HROW)	$1.9B
Ocular Therapeutix (OCUL)	$1.7B
Xencor (XNCR)	$1.7B
ARS Pharmaceuticals (SPRY)	$1.7B
BioCryst Pharmaceuticals (BCRX)	$1.6B